VMI
CTMX icon

VHCP Management II’s CytomX Therapeutics CTMX Stock Holding History

VHCP Management II’s Portfolio CTMX Stock Details CTMX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-288,915
Closed -$4.48M – 22
2017
Q2 		$4.48M Hold
288,915
– – 1.79% 11
2017
Q1 		$4.99M Sell
288,915
-288,916
-50% -$3.8M 2.04% 9
2016
Q4 		$6.35M Hold
577,831
– – 3.05% 8
2016
Q3 		$9.06M Hold
577,831
– – 4.65% 6
2016
Q2 		$5.91M Hold
577,831
– – 3.56% 9
2016
Q1 		$7.43M Sell
577,831
-25,200
-4% -$350K 4.89% 8
2015
Q4 		$11.6M Buy
+603,031
New +$9.54M 9.56% 5

Other funds holding CTMX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

VHCP Management II's CTMX Position: Q3 2017 in Review

VHCP Management II sold out of CytomX Therapeutics (CTMX) in Q3 2017, closing a stake of 288,915 shares — an estimated $4.48M sold.

VHCP Management II first reported a position in CTMX in Q4 2015 and held it in 7 quarters. The position peaked at $11.6M in Q4 2015. 97 funds tracked by Wall St. Rank hold CTMX as of Q3 2017.

  • VHCP Management II reported no remaining CytomX Therapeutics position as of Q3 2017 after selling out during the quarter.
  • VHCP Management II sold 288,915 CytomX Therapeutics shares in Q3 2017, an estimated $4.48M.
  • VHCP Management II first reported a position in CytomX Therapeutics in Q4 2015 and held it in 7 quarters.
  • VHCP Management II's CytomX Therapeutics position peaked at $11.6M in Q4 2015.
  • 97 funds tracked by Wall St. Rank held CytomX Therapeutics as of Q3 2017.

Based on VHCP Management II's 13F filing for Q3 2017, filed 13 Nov 2017.